Showing 91-100 of 106 results for "".
Case Report: Henoch-Schönlein Purpura in an Adult; Resident Salary Report
https://practicaldermatology.com/youngmd-connect/resident-resource-center/case-report-henoch-schnlein-purpura-in-an-adult-resident-salary-report/20909/Trends and Trendsetters of 2014
https://practicaldermatology.com/topics/general-topics/trends-and-trendsetters-of-2014/21259/Highlights from the year, including fresh ideas from industry and innovations from physicians.Scurvy in the Modern Era
https://practicaldermatology.com/topics/general-topics/scurvy-in-the-modern-era/21456/One of the winning presentations given by dermatology residents at Cosmetic Surgery Forum.Critical Factors to Advancing Melanoma Diagnosis and Treatment
https://practicaldermatology.com/topics/skin-cancer-photoprotection/critical-factors-to-advancing-melanoma-diagnosis-and-treatment/22970/Dermatologists need to stay abreast of technologies for evaluation of lesions and ensure that medical oncologists within their referral network recognize the importance of clinical trials.Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments/21990/Recent Developments
https://practicaldermatology.com/columns/recent-developments/PD0509_05-php/22827/Lead Psoriasis Patients Along the Path to Clearance
https://practicaldermatology.com/topics/psoriasis/PD0209_01-php/22873/With so many effective therapies now available, dermatologists must be prepared to guide their patients to the right treatment for their specific presentation.- FDA Clears Candela's Vbeam 595 nm Pulsed Dye Laser for the Treatment of Port Wine Stains and Hemangiomas in the Pediatric Populationhttps://practicaldermatology.com/news/fda-clears-vbeam-595-nm-pulsed-dye-laser-for-the-treatment-of-port-wine-stains-and-hemangiomas-in-the-pediatric-population/2461824/The U.S Food and Drug Administration has cleared candela’s Vbeam family of 595 nm wavelength pulsed dye lasers (PDL) to treat cutaneous capillary malformations, and infantile hemangiomas (IH)/congenital hemangiomas in the pediatric population (from birth – 21 years of age).
- Pierre Fabre Dermatologie Receives the Prix Galien Award for Pharmaceutical Research for Hemangiolhttps://practicaldermatology.com/news/pierre-fabre-dermatologie-receives-the-prix-galien-award-for-pharmaceutical-research-for-hemangiol/2459047/Pierre Fabre Dermatologie, a subsidiary of Pierre Fabre Dermo-Cosmetics, was distinguished by the Prix Galien award (France) for Hemangiol, an oral pediatric propranolol solution specifically developed for some severe infantile hemangiomas. Hemangiol® was successively approved by Americ
- Pierre Fabre Obtains FDA Approval to Market Hemangeol for the Treatment of Infantile Hemangiomahttps://practicaldermatology.com/news/20140319-pierre_fabre_obtains_fda_approval_to_market_hemangeol_for_the_treatment_of_infantile_hemangioma/2459311/Pierre Fabre Dermatologie has obtained marketing authorization from the FDA for the pediatric drug Hemangeol (propranolol hydrochloride), which is the first and only approved treatment for “proliferating infantile hemangioma requiring s